Multilineage dysplasia was advanced by the World Health Organization to increase prognostic accuracy in myelodysplastic syndromes (MDS) classification. We performed a structured cytomorphological examination of bone marrow (BM) in 221 low-grade MDS patients, this in conjunction with strict guidelines for cytopenias. A dysplasia scoring system was developed utilizing dysplastic changes, which were associated with worse outcome on univariate and multivariate analysis corrected for the International Prognostic Scoring System (IPSS). Dysplasia X10% in one BM lineage and one cytopenia constituted the low-risk category UCUD or Unilineage Cytopenia and Unilineage Dysplasia. The high-risk category comprised patients with cytopenia in X2 lineages and dysplasia in X2 BM lineages, namely MCMD or Multilineage Cytopenia and Multilineage Dysplasia. Intermediate-risk patients had one cytopenia and multilineage dysplasia, or cytopenia in X2 lineages and unilineage BM dysplasia, designated UCMD/MCUD or Unilineage Cytopenia and Multilineage Dysplasia/Multilineage Cytopenia and Unilineage Dysplasia. This system utilizing cytopenia-dysplasia scoring at diagnosis enabled comprehensive categorization of low-grade MDS cases that predicted for overall as well as leukemia-free survival. Cytopenia-dysplasia categorization added additional prognostic values to the lower risk IPSS categories. This suggests that a standardized dysplasia scoring system, used in conjunction with cytopenia, could improve diagnostic and prognostic sub-categorization of MDS patients.
Introduction
The myelodysplastic syndromes (MDS) have the general epithet of refractory anemia in the French-American-British (FAB) and recent World Health Organization (WHO) classification. However, MDS develops because of genetic damage in the multipotent hematopoietic stem cell, therefore most 'refractory anemias' are in fact accompanied by varied degrees of abnormality in the concentration or morphology of leukocytes and platelets. 1 This leads to a wide spectrum of disease phenotypes and heterogeneity in cytomorphological disease subsets. [2] [3] [4] The FAB classification remains the standard against which all new cytomorphological classification systems are evaluated and its five subsets predict the risk of evolution towards acute myeloid leukaemia (AML).> Nevertheless, the great disparity in outcome within the different subgroups limits its utility as a model for predicting prognosis in individual patients. The International Prognostic Scoring System (IPSS) is a powerful instrument to improve on this; however, its refined subdivision of blast percentages has no bearing on low-grade MDS. 5 This may partly explain the added value of histopathological variables such as abnormal localization of immature precursors (ALIP) and increased CD34 immunostaining for prognostication within these subgroups. 6 In 1999, the WHO published the first of its proposals to update MDS classification. 7, 8 The indolent or low-grade group of MDS, namely refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) as found in the FAB classification, has been subdivided into no less than six disease subsets: RA, RARS, refractory cytopenia with multilineage dysplasia (RCMD), RCMD with ringed sideroblasts (RCMD-RS), MDS associated with isolated del(5q) and MDS, unclassified (MDS-U). This sub-division of low-grade MDS is based on introducing uni-versus multilineage dysplasia as criteria and creating a good prognostic cytogenetic subset, the 5qÀ syndrome. An unclassified group remains.
The presence of multilineage dysplasia predicts an unfavorable outcome in low-grade MDS. 4, [9] [10] [11] [12] In this regard, Matsuda et al. 13 and Tassin et al. 14 carried out valuable work in creating dysplasia scoring systems even before the advent of the WHO proposal. The first system relied on the pseudo Pelger-Huet (PPH) anomaly, hemoglobin level and micromegakaryocytes, the other mainly on the PPH anomaly and agranularity versus hypogranularity. Notwithstanding these findings, the WHO classification is still lacking in a structured and reproducible approach for the precise definition and quantification of dysplastic bone marrow (BM) features. Moreover, the precise relationship of cytopenia in relation to dysplasia needs to be clarified. In the proposal, unilineage erythroid dysplasia clearly presupposes unilineage anemia. 8 It is unclear whether anemia in the absence of any other cytopenia, but accompanied by multilineage dysplasia, should be designated unilineage (RA and RARS) or multilineage (RCMD and RCMD-RS). We addressed these questions by retrospectively examining the disease classification of a group of low-grade MDS patients employing systematic cytomorphological study and detailed follow-up.
Patients and methods

Patients
Two hundred and forty-four low-grade (FAB RA and RARS) MDS patients, consecutively diagnosed and followed at the University Hospital of Leuven, Belgium, between 1990 and 2004, were included in this retrospective analysis. No cases with therapyrelated MDS or cytopenias owing to known toxic exposure and systemic diseases were included. Informed consent was provided in accordance with institutional practices. All patients underwent routine BM investigation with cytogenetic analysis at diagnosis. Twelve cases had to be excluded because cytological preparations were unavailable or were of poor quality. Additionally, retrospective evaluation had to ascertain a clinical evolution consistent with MDS. Therefore, two patients, both with mild pancytopenia and dysplasia and with no evidence of toxic exposure, were excluded because their blood values spontaneously recovered 3 and 6 years after diagnosis. Through a detailed review of the cytological preparations in 230 remaining cases, two patients were reclassified as myeloproliferative disease, two cases as CMML and five patients as RAEB, thus final analysis included 221 patients.
End points. Follow-up was complete regarding death and disease progression until August 2005. Disease progression was defined as proliferative when a sustained and significant neutrophil leukocytosis developed, as CMML in cases developing peripheral monocytosis 41 Â 10 9 /l, as RAEB in cases with X5% but o20% BM blasts on follow-up, and as AML, defined according to the WHO as the development of X20% blasts in BM or peripheral blood (PB). All these events were recorded as time to progression (TT-Progression). AML evolution was also recorded separately as time to AML (TT-AML). Other end points included development of additional cytopenias, of transfusion dependence and of additional karyotypic abnormalities.
Statistical analysis. The relationship between the dysplastic features and the different MDS classifications and overall survival (OS), TT-AML and TT-Progression was assessed using the product limit method of Kaplan-Meier. The P-values for these analyses are based on the log-rank test. Rates of transfusion, karyotypic evolution and progression to death, AML and disease progression were compared by Pearson's w 2 test. To verify whether there were important differences in the extent of dysplasia among the different categories of the various classification systems, the Kruskall-Wallis test was applied. The Cox proportional hazards model was used to assess the joint effects of all dysplastic features and the various MDS classification systems on the one hand and the IPSS score on the other. All analyses were performed with the SAS system, version 8.1 (SAS Institute, Cary, NC, USA)
FAB classification
All patients were diagnosed and subtyped based on the morphological examination of PB and BM smears according to the FAB proposal.
2 BM aspirates were stained with MayGrunwald-Giemsa and iron stain. At least 400 nucleated BM cells and 100 PB cells were studied.
PB cytopenia. The distribution of normal values in a laboratory or clinical guideline is insufficient for defining the lower limit of normal in an ageing population. 15 We opted for the clarity of an easily recognizable lower limit of normal set at just below our laboratory threshold to diagnose cytopenia. The chosen hemoglobin level (13.5 g/dl in men and 11.5 g/dl in women) was less than normal for our laboratory (14 and 12 g/dl, respectively) and showed an excellent correspondence with recent conclusions of Beutler et al. 15 on the lower limit of normal hemoglobin concentration in patients over 50 or 60 years of age. Likewise, the lower limit of normal for leukocytes and thrombocytes was set at 3.5 Â 10 9 /l and 135 Â 10 9 /l, respectively (normal values for our laboratory 4 Â 10 9 /l and 150 Â 10 9 /l, respectively), to decrease the likelihood of diagnosing clinically irrelevant cytopenia in an ageing population.
WHO classification BM cytology. A detailed analysis was performed of the dysplastic features on BM for reclassification. We used the 10% WHO threshold to record dysplasia in each lineage. Hundred nucleated erythroid cells were counted and classified for their most apparent dysplastic change: for example, a cell expressing nuclear budding could be megaloblastoid too, but was classified only once as nuclear budding. The distribution of erythroid dysplasia in 100 cells was counted into six categories (normal, nuclear budding/lobation/bridging, basophilic stippling, vacuolization, multinuclearity and megaloblastoid changes); categories added up to give percentage erythroid dysplasia. The myeloid lineage was then evaluated separately for cytoplasmic and nuclear changes. Hundred myeloid cells from promyelocyte to neutrophil stage were studied to establish the extent and distribution of nuclear aberrations in eight categories (normal, small, giant and ring forms; mono-and bi-lobar pseudo PelgerHuet (PPH) forms; and two novel clumped nuclear forms: one with filamentous excrescences projecting centripetally and a lobulated hyposegmented form, see Figure 1 ). Cytoplasmic granularity in another 100 cells were counted in four categories (normal, agranulation, hypogranulation, and aberrant or hypergranulation). In the myeloid lineage, dysplasia was recorded when 10% dysplasia of either the nucleus or the cytoplasm was present. Finally, 100 megakaryocytes were studied for dysplastic features in four categories (normal, micromegakaryocytes, large monolobar forms, and dispersed or bizarre hyperlobulated nuclei). In 62% of cases, 100 megakaryocytes could be evaluated and in 90% of cases X10 megakaryocytes were studied.
BM histology. A trephine biopsy of good quality was available in 156 (79%) patients at diagnosis. BM biopsy contributed to the assessment of morphology and cellularity. BM histology was especially important to evaluate megakaryocyte atypia in the 19 cases where megakaryocytes on cytology, even after repeated BM aspirations, were scanty and difficult to evaluate.
Cytogenetic analysis. Cytogenetic analysis of BM specimens was carried out according to standard procedures at our institution after short-term culture as described previously. 6, 16 In 15 cases (7%), cytogenetic analysis was not available. In 67% of cases, repeated examinations of the karyotype was carried out over the course of the disease (range 1-17, median three times). Karyotypic evolution was recorded if a new abnormality developed in cases with a normal karyotype or p2 aberrations. Evolution within a complex karyotype was not an end point.
IPSS classification
Prognostic risk was calculated according to the IPSS (BM blasts, cytopenias and karyotype). Cytopenias were defined as a hemoglobin level of o10 g/dl, an absolute neutrophil count of o1.8 Â 10 9 /l and a platelet count of o100 Â 10 9 /l.
Results
Univariate analyses Cytological findings. Shown in Figure 1 and Table 1 .
Bone Marrow. Erythroid dysplasia as expressed in megaloblastoid changes was not associated with poor outcome, in contrast to the more specific erythroid dysplastic parameters such as nuclear budding, basophilic stippling, vacuolization and multinuclearity. Myeloid nuclear dysplasia correlated with unfavorable survival, especially as expressed in monolobar pelgeroid forms, clumped hyposegmented forms and small forms. The prognostic significance of myeloid cytoplasmic dysplasia on BM was particularly related to agranularity, not to hypo-or hypergranularity. The evaluation of neutrophil dysplasia in PB correlated with the findings regarding neutrophils in BM (data not shown). The presence of megakaryocytic dysplasia and, in particular, micromegakaryocytes was strongly associated with an adverse outcome for survival, TT-P and TT-AML (Po0.0001).
FAB classification
Two hundred and twenty-one patients were classified as RA (n ¼ 157) and RARS (n ¼ 64); 67 women and 154 men. Median age was 69 years (range 23-92). Survival and evolution are shown in Figure 2 and Table 2 . At last time of follow-up, 86 patients (39%) were alive and median survival is 60 months. Median time of follow-up is 45 months (range 2-185).
WHO classification
The WHO classification was applied according to its published guidelines and could define different subgroups for survival, MDS progression and AML evolution ( Figure 2 and Table 2 ). Figure 3 gives a schematic representation of the reclassification of low-risk MDS. After reclassification according to the WHO, 13 patients (6%) had only anemia and unilineage erythroid dysplasia: five with RA, eight with RARS. According to the criteria of cytopenias and multilineage dysplasia, 87 patients (39%) could be reclassified as refractory cytopenia with multilineage dysplasia (RCMD) and 15 patients (7%) as refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS).
Unclassifiable patients in the WHO proposal. Only a small minority of patients were classified as RA and RARS according to the WHO proposal, because most 'refractory anemias' had X10% dysplasia in another lineage too. As anemia only was present, classifying them as RCMD or RCMD-RS was not correct according to the WHO and neither could these cases be described as pure sideroblastic anemia. Two intermediate categories were created: 26 patients had refractory anemia with multilineage dysplasia (RA-MLD) and 39 had RARS with multilineage dysplasia (RARS-MLD). Thirty-two patients could be classified as MDS-U. Of these, 17 had neutropenia or thrombopenia in combination with dysplasia of either myeloid or megakaryocytic lineage, or both. Another 15 cases had anemia plus at least one other cytopenia but X10% dysplasia in one myeloid cell line only. As discussed later, although these patients clearly evolved as myelodysplastic disease, they nevertheless defied classification into other WHO subgroups.
Sub-analysis of WHO subgroups. The three low-risk WHO subgroups (RA, RARS and 5qÀ syndrome) could not be distinguished from each other for outcome (P-values not significant). Likewise OS and TT-AML in the high-risk groups RCMD and RCMD-RS were not significantly different. The MDS-U subset was not distinguishable from the three low-risk groups for survival, however, compared to RCMD patients showed extended survival (Po0.0001) and time to leukemic evolution (P ¼ 0.018). RA-MLD patients, that is, anemia with multilineage dysplasia, survived shorter than unilineage RA (P ¼ 0.05), yet outcome for survival and leukemic evolution was not statistically different from the RCMD subset. In the subsets with ringed sideroblasts, a marked difference in survival was noted between unilineage RARS and RCMD-RS (P ¼ 0.0008), but not between RARS and RARS-MLD (P ¼ 0.3). Images were acquired using a Leica DMLB microscope, original magnification Â 1000, with Leica DC300 camera and processed using Leica IM1000 image manager (Leica Camera AG, Solms, Germany). Figure 2 ).
Multivariate analyses
Refined dysplasia scoring system Table 1 displays the variables of interest shown to be associated with outcome after correction for IPSS risk. The independent prognostic significance of megakaryocytic dysplasia is seen when corrected for the IPSS. All three categories of megakaryocyte dysplasia were strongly associated with outcome and thus incorporated into the scoring system. However, we decided to simplify the scoring of erythroid and myeloid dysplasia by utilizing only those parameters associated with shorter survival or time to leukemic evolution on univariate and multivariate analysis. Moreover, these dysplastic changes were easily detectable, which could contribute to the standardization of dysplasia in routine investigation. This meant that megaloblastoid changes, which had no prognostic impact, were not calculated into the final erythroid score. Megaloblastoid changes can be very subtle and on a continuum with normal BM, and the threshold for their recognition notoriously difficult to standardize between different observers. Nuclear budding and bridging, multinucleation, vacuolization and basophilic stippling, on the other hand, can be readily distinguished from normal and if present in X10% of the erythroid lineage, outcome is significantly worse. In the myeloid range, we could confirm the strong prognostic impact of agranularity, whereas hypo-and hypergranularity were not associated with prognosis. 12 This led to a simplified myeloid cytoplasmic score, based solely on agranularity. Analysis of the myeloid nuclear abnormalities led to seven different categories of dysplasia of which three were retained for the scoring system. Small forms had prognostic impact and were detected in the full range of maturating myeloid cells, but were most obviously recognized as small myelocytes and metamyelocytes with compact, contracted nuclei. Monolobar pelgeroid forms and clumped hyposegmented forms added up to the simplified score for myeloid nuclear dysplasia. It could be speculated that monolobar and clumped hyposegmented neutrophils signify an intensified form of abnormal nuclear lobulation above the bi-lobed form, which might explain their prognostic impact. 17 
Cytopenia-dysplasia categorization
This novel dysplasia scoring system gave us simplified and significant dysplastic criteria by which to define different patient subsets. Survival and evolution are shown in Figure 2 and Cytopenia-dysplasia categorization in low-risk MDS E Verburgh et al Table 2 and a schematic representation is shown in Figure 3 and Table 3 . Patients now fell readily into three broad categories.
UCUD. The first category, designated UCUD, consisting of patients with Unilineage Cytopenia and Unilineage Dysplasia, included the WHO subset of RA and RARS. Additionally, owing to the refined minimum criteria for dysplasia, 22 patients with less significant dysplasia were recruited from the 'unclassifiable' cases ( Figure 3 ). Note that in 18 UCUD cases, cytopenia did not correspond with dysplasia in the same lineage at diagnosis. The 5qÀ syndrome was also placed in the low-risk subset.
MCMD. The term 'refractory cytopenia' was used in the past for MDS cases with thrombocytopenia or leucopenia (in the WHO proposal these patients are unclassified). This makes RCMD(-RS) a confusing term for patients with Multilineage Cytopenia and Multilineage Dysplasia, and the high-risk category was thus designated MCMD. As applied using more stringent dysplastic criteria, only 76 patients remained in this category, 27 were removed to the intermediate category.
UCMD/MCUD. The patients in the intermediate group were
strictly defined as having Unilineage Cytopenia, yet with Dysplasia threshold. We applied the suggested 10% threshold in the WHO categorization as well as our simplified categorization as seen in Table 3 . Note that the simplified scoring system utilizes only parameters associated with poor outcome on uni-and multivariate analysis and excludes mild dysplastic changes.
Cytopenia-dysplasia categorization in low-risk MDS E Verburgh et al
Interobserver correlation. Twenty patients were randomly selected to be evaluated by an independent observer (GV) according to the WHO classification (in its modified form including two categories for RA and RARS with multilineage dysplasia) as well as the cytopenia-dysplasia categorization. The interobserver agreement was 95% for both the WHO and the cytopenia-dysplasia categorization.
Disease evolution in different classifications
Shown in Tables 2, 4 Transfusion. Both hemoglobin level and development of transfusion dependency did not differ between FAB subgroups. In the WHO proposal, IPSS and cytopenia-dysplasia categorization, the high-risk groups were more likely to proceed to transfusion dependence.
Disease progression. Five patients developed proliferative disease with high neutrophil leukocytosis resembling atypical chronic myeloid leukemia at a median of 17 months (range 5-29), with no excess BM blasts at that stage. CMML developed in seven patients (3%) and RAEB in 36 patients (16%) of which 15 known to progress to AML. Additionally, 21 patients (10%) developed AML (16% in total). Leukemic evolution was associated with the subsets of the WHO and the cytopeniadysplasia categorization, but not with IPSS or FAB subsets.
Karyotypic evolution. Abnormal karyotype and karyotypic evolution were more likely to occur in the higher risk groups of the WHO classification and the cytopenia-dysplasia categorization.
Evolution in MDS-U patients. Fifteen of these patients had multilineage cytopenia with 410% dysplasia in one BM lineage only (five erytroid, five megakaryocytic, five myeloid) at diagnosis. Transfusion dependence developed in 10/15, including progression to RAEB (n ¼ 2) and AML (n ¼ 2) and karyotypic evolution (n ¼ 4). The other 17 MDS-U patients had either myeloid or megakaryocytic dysplasia, or both, expressed as thrombocytopenia (n ¼ 15) and neutropenia (n ¼ 2). Additional cytopenias developed in 14/17 cases, including RAEB (n ¼ 3) and karyotypic evolution (n ¼ 3). In 2/3 patients not developing additional cytopenias, a 20qÀ deletion was present. Both patients are stable after 45 years follow-up in spite of severe thrombocytopenia not responsive to immunosuppressive therapy.
Evolution in low-risk patients. Erythroid dysplasia, being mildly megaloblastoid in unilineage RA cases, was only 5-10% when refined according to our scoring system, yet 3/5 patients developed additional cytopenias and 2/5 transfusion dependence. Two patients with 5qÀ syndrome developed RAEB and AML, with stable karyotype at respectively, 2.5 and 3.5 years after diagnosis. Leukemic evolution was not seen in RA and RARS cases.
The IPSS and the cytopenia-dysplasia categorization Table 4 shows the lack of independent prognostic information of the IPSS when applied to the cytopenia-dysplasia subgroups. In Table 5 the cytopenia-dysplasia categorization is applied on IPSS subgroups. In the low and intermediate-1 IPSS subgroups, this categorization could add prognostic value.
Discussion
The WHO classification is an important step towards a better disease definition of MDS. Nevertheless, some find its reliance on the FAB framework a timid approach to change. 1 Others argue that its new criteria are not yet evidence-based. 18 We applied the WHO criteria on a low-risk MDS population and agree with other investigators that, overall, there are significantly different sub-sets for survival and disease evolution. 11, [19] [20] [21] Multilineage dysplasia in MDS does indeed confer unfavorable survival compared to unilineage dysplasia. However, partly owing to the uneven distribution of patients, and partly owing to the increased number of subsets still based on the FAB framework, many subgroups are indistinguishable from each other.
11,19-21 Howe et al.
21
concluded in their study of the WHO classification that the increased number of diagnostic categories will make application of statistics in studies impossible unless patient groups are extremely large. This raises the question if the sub-categorization of the WHO is based on arbitrary 'splitting' instead of evidencebased 'lumping'. As expected and in accordance with the findings of others, in the WHO we could not distinguish the outcome of RA from that of RARS, or RCMD from RCMD-RS. 11, 21, 22 In fact, the lumping together of certain WHO categories have increasingly been advocated. 11, 22 Moreover, in our hands, many straightforward MDS cases defied classification into the WHO framework. Our results emphasized the need for a more precise definition of dysplasia in relation to cytopenia. To this end, we developed a structured system of cytopenia-dysplasia categorization based on the relationship of PB cytopenia to BM lineage dysplasia.
There is consensus that disorders with ringed sideroblasts are heterogeneous and cannot be lumped into a single entity. 4, 9 An increased number of ringed sideroblasts can also occur in CMML and RAEB patients, and in these cases, it does not dictate the classification. Garand et al. 4 and Germing et al. 9 showed that pure sideroblastic anemia (PSA) confers a survival advantage over RARS associated with additional dysplastic features. However, a sizeable proportion of their PSA cases had leuko-or thrombopenia, not anemia only as described by the WHO. Additionally, they used a much higher threshold (30 and 40%, respectively) for megakaryocytic dysplasia, not the 10% of the WHO. Strictly applied, the WHO criteria delineates a much smaller unilineage population. In their series, Sanz et al. 23 and Nosslinger et al. 19 had much lower proportions of unilineage patients (17 and 8%, respectively) and failed to demonstrate a difference in outcome of unilineage RARS compared to RCMD-RS.
We found that RARS cases survive significantly longer than RCMD-RS cases; however, the RARS subset comprised only 8/64 cases with ringed sideroblasts (13%). Indeed, most 'refractory anemias' have cytopenia or dysplasia in another lineage too, leaving only a few patients in the RA and RARS categories. Our patients with anemia only, yet with BM dysplasia additional to only the eythroid lineage (RA-MLD and RARS-MLD), seemed to fit somewhere in between RA and RCMD, RARS and RCMD-RS, hinting at a continuum of disease expression, the extent and duration thereof dictating whether one or more cytopenias will develop. Simply classifying these patients as RA or RARS negates the importance of multilineage dysplasia and defeats its introduction into the classification, since patients could then be easily classified solely by utilizing one or more peripheral blood cytopenias.
'Single lineage erythroid' RA and RARS cases were thus infrequently diagnosed in our population, which is in keeping with the phenotype of a clonally involved multipotent progenitor cell and the generally held requirement for dysplasia in at least two BM lineages in MDS. In more than 50% of MDS, BM karyotype is normal, therefore the diagnosis has to be established on cytomorphological grounds. BM histology should be studied in addition to cytology, with a keen regard for cellularity, disorganized growth patterns including ALIP, and especially megakaryocyte atypia. In almost 10% of our cases megakaryocyte morphology could be ascertained only on histological examination and was indispensable to arrive at a diagnosis in some cases.
Clinical observation and diagnostic restraint is needed in doubtful cases. Indeed, some 'MDS-unclassified' cases pre- Figure 3 The re-classification of low-grade MDS. Table 3 Prognostic Cytopenia-dysplasia Categorization for low-grade MDS sented without erythroid dysplasia or anemia at diagnosis, and occasionally with dysplasia in only one lineage. Also, RA cases are loath to display significant dysplasia. The absence of decisive diagnostic features in these cases, necessitates a time period to assess evolution and rule out other diseases. The aim of the study was to be inclusive of initially unclassifiable MDS cases in which evolution was nevertheless consistent with MDS. Indeed, our observations over time confirm that the majority of these patients developed transfusion dependence or additional cytopenias. Additionally, a 19% incidence of MDS progression occurred, even though progression-free survival was long (97 months). Patients with less cytopenias and less dysplasia at diagnosis clearly had a superior overall and progression-free survival. It would appear that the WHO had opened a door half-way on a new understanding of MDS based on the extent of dysplasia, although not yet put into proper perspective with the extent of cytopenia, which is certainly one of the strongest indicators of progression in MDS. 5, [24] [25] [26] If multilineage dysplasia is to become a standard for classification in MDS, a structured and uniform approach is urgently needed. 27, 28 Dysplasia thus emerges not merely as a criterium for diagnosis, but as a promising tool for MDS prognostication at diagnosis. We decided to employ a simplified score, utilizing only dysplastic parameters significantly associated with outcome for survival or disease evolution. Certain parameters, but most notably those of the megakaryocytic lineage, were also independently associated with outcome in the IPSS classification ( Table 1 ). The parameters employed are easily recognizable. For example, the focus is on specific dysplastic changes in the erythroid lineage rather than debatable megaloblastoid changes. In the myeloid lineage, agranularity is less equivocal to assess than the range of hypogranularity encountered. We used this simplified scoring system, combined with a strict definition of cytopenia at diagnosis, to define patients in three broad categories: a low-risk 'unilineage' group UCUD, a high-risk 'multilineage' group MCMD and an intermediate risk group UCMD/MCUD. This categorizes MDS patients clearly on baseline criteria and predicts their behavior. The low-risk group is precisely what its name entails: low-risk, and can well require months of observation in the absence of a typical karyotypic aberration before a diagnosis is made. We observed a low rate of disease progression in these patients. Decisions regarding therapeutic intervention can be simplified, because a truly indolent group inclusive of low-risk patients, as well as an intermediate group UCMD/MCUD with increased likelihood of disease progression, is identified. The high-risk MCMD group was associated with poor-risk karyotype, increased transfusion dependence and decreased leukemia-free and overall survival.
The IPSS has one variable in common with our categorization, but at a lower threshold, namely cytopenia. In low-risk MDS, karyotype is the unique variable of the IPSS, while dysplasia uniquely determines our subsets. In the low and intermediate-1 risk IPSS subgroups, cytopenia-dysplasia scoring shows its independent prognostic value. The IPSS, on the other hand, adds no prognostic value to the Cytopenia-Dysplasia subgroups, hinting at an already existing correlation between abnormal karyotype and dysplasia, as found in AML. 29, 30 It is conceivable that molecular and genetic investigation might uncover subsets other than just the 5qÀ deletion, which will improve risk stratification and open up molecular therapeutic pathways. However, a refined and standardized dysplasia scoring system could aid in this research, for example, by improving patient categorization before gene analysis.
The diagnosis of MDS is made at a point in time of progression of an underlying clonal evolution. The underlying pathobiology, however, does not evolve equally in all patients. Thus, the relevance of distinguishing between one or more cytopenias, and between uni-and multilineage dysplasia: it reveals something of the severity and prognosis of the underlying disorder. We would reason that these diseases remain a true syndrome at present: exhibiting the common characteristics of BM dysplastic (hyper)activity and peripheral cytopenias, the variable occurrence of karyotypic and leukemic evolution, with an as yet obscure underlying etiology involving the multipotent Table 4 The effect of the IPSS classification on overall survival and AML-free survival Abbreviations: AML, acute myeloid leukaemia; MCMD, multilineage cytopenia with multilineage dysplasia; MCUD, multilineage cytopenia with unilineage dysplasia; NR, not reached; UCUD, unilineage cytopenia with multilineage dysplasia; mo, months. progenitor cell. Our categorization recognizes this limitation, yet by utilizing readily available routine BM investigation in a systematic way, it provides a clinically relevant sub-division of low-risk MDS patients. This framework provides sufficiently inclusive yet clearly delineated patient groups in which to further explore the biology and therapy of low-risk MDS.
